RayzeBio develops novel peptide mimetic binders to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/13/2022 | Series D | $159.75MM | $xx.xx | $599.64MM | Viking Global Investors, Sofinnova Investments, Wellington Management, Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital | |
Price per Share
$xx.xx
Shares Outstanding
63,972,982
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Viking Global Investors, Sofinnova Investments, Wellington Management, Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital
|
||||||
06/15/2021 | Series C | $99.63MM | $xx.xx | $651.39MM | Venrock Healthcare Capital Partners, Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, CG X, venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments | |
Price per Share
$xx.xx
Shares Outstanding
23,999,996
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Venrock Healthcare Capital Partners, Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, CG X, venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments
|
||||||
12/08/2020 | Series B | $96.86MM | $xx.xx | $237.83MM | Venrock Healthcare Capital Partners, OrbiMed, Redmile Group, Viking Global Investors, Logos Capital, Cormorant Asset Management, LifeSci Venture Partners, Alexandria Venture Investments, venBio Partners, Versant Ventures, Samsara BioCapital | |
Price per Share
$xx.xx
Shares Outstanding
46,666,672
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Venrock Healthcare Capital Partners, OrbiMed, Redmile Group, Viking Global Investors, Logos Capital, Cormorant Asset Management, LifeSci Venture Partners, Alexandria Venture Investments, venBio Partners, Versant Ventures, Samsara BioCapital
|
||||||
10/14/2020 | Series A | $41.51MM | $xx.xx | $55.35MM | venBio Partners, Versant Ventures, Samsara BioCapital | |
Price per Share
$xx.xx
Shares Outstanding
45,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
venBio Partners, Versant Ventures, Samsara BioCapital
|